In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Moderna (MRNA), with a price target of $108.00. The company’s shares closed last Thursday at $71.28.
According to TipRanks.com, Singh is a 4-star analyst with an average return of 8.3% and a 42.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Moderna is a Moderate Buy with an average price target of $93.36, a 36.6% upside from current levels. In a report released yesterday, Needham also assigned a Buy rating to the stock with a $94.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $95.21 and a one-year low of $15.52. Currently, Moderna has an average volume of 9.95M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Read More on MRNA:
